

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 April 2006 (13.04.2006)

PCT

(10) International Publication Number
WO 2006/039237 A1

(51) International Patent Classification:
A61K 9/14 (2006.01) *A61K 31/445* (2006.01)

(21) International Application Number:
PCT/US2005/034433

(22) International Filing Date:
28 September 2005 (28.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/614,139 29 September 2004 (29.09.2004) US

(71) Applicant (for all designated States except US): **CORDIS CORPORATION** [US/US]; 14201 N.W. 60th Avenue, Miami Lakes, Florida 33014 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MARYANOFF, Cynthia A.** [US/US]; 4029 Devonshire Drive, Forest Grove, Pennsylvania 18922 (US). **SIX, Karl Pieter Laura Stefaan** [BE/BE]; Kallebeekstraat 65, B-3190 Boortmeerbeek (BE). **VANDECRUYS, Roger Petrus Gerebern** [BE/BE]; Langstraat 108, B-2260 Westerlo (BE).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL DOSAGE FORMS OF STABLE AMORPHOUS RAPAMYCIN LIKE COMPOUNDS



(57) Abstract: The present invention provides a pharmaceutical dosage form comprising stable amorphous rapamycin like compounds and a pharmaceutically acceptable excipient and methods of making the pharmaceutical dosage form.

- 1 -

PHARMACEUTICAL DOSAGE FORMS OF STABLE AMORPHOUS RAPAMYCIN LIKE COMPOUNDS

Field of Invention

This application claims the benefit of provisional patent application 60/614,139 filed September 29, 2004, which is hereby incorporated herein by reference.

The present invention relates to a pharmaceutical dosage form for delivery of stable amorphous rapamycin like compounds.

Background of the Invention

Rapamycin is a macrocyclic triene antibiotic produced by *Streptomyces hygroscopicus* as disclosed in U.S. Patent No. 3,929,992. It has been found that rapamycin among other things inhibits the proliferation of vascular smooth muscle cells in vivo. Accordingly, rapamycin may be utilized in treating intimal smooth muscle cell hyperplasia, restenosis, and vascular occlusion in a mammal, particularly following either biologically or mechanically mediated vascular injury, or under conditions that would predispose a mammal to suffering such a vascular injury. Rapamycin functions to inhibit smooth muscle cell proliferation and does not interfere with the re-endothelialization of the vascular walls.

Rapamycin reduces vascular hyperplasia by antagonizing smooth muscle proliferation in response to mitogenic signals that are released during vascular injury. Inhibition of growth factor and cytokine mediated smooth muscle proliferation at the late G1 phase of the cell cycle is believed to be the dominant mechanism of action of rapamycin. However, rapamycin is also known to prevent T-cell proliferation and differentiation when

- 2 -

administered systemically. This is the basis for its immunosuppressive activity and its ability to prevent graft rejection.

Previously known forms of amorphous rapamycin did not have optimum shelf lives. The present invention provides amorphous rapamycin that is stable for extended period of time and is capable of being processed into pharmaceutical dosage forms, incorporated into drug delivery systems and coated on medical devices.

Summary of the Invention

The present invention provides a pharmaceutical dosage form comprising stable amorphous rapamycin like compounds and a pharmaceutically acceptable excipient.

Detailed Description of the Invention

As used herein, "**rapamycin like compounds**" as used herein includes rapamycin and all analogs, derivatives and conjugates that bind to FKBP12, and other immunophilins and possesses the same pharmacologic properties as rapamycin, including inhibition of the target of rapamycin (TOR). Sirolimus is a rapamycin also known as (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*, 26*R*,27*R*,34*aS*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34*a*-hexadecahydro-9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4] oxazacyclohentacontine-1,5,11,28,29(4*H*,6*H*,31*H*)-pentone.

- 3 -

Other analogs, derivatives and conjugates that may be processed into a substantially solvent free amorphous solid include, but are not limited to, 40-O-(2-Hydroxyethyl)rapamycin (everolimus), 40-O-Benzyl-rapamycin, 40-O-(4'-Hydroxymethyl)benzyl-rapamycin, 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin, 40-O-Allyl-rapamycin, 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin, (2'E,4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin, 40-O-(3-Hydroxy)propyl-rapamycin 40-O-(6-Hydroxy)hexyl-rapamycin 40-O-[2-(2-Hydroxy)ethoxy]ethyl-rapamycin 40-O-[(3S)-2,2-Dimethyldioxolan-3-yl]methyl-rapamycin, 40-O-[(2S)-2,3-Dihydroxyprop-1-yl]-rapamycin, 40-O-(2-Acetoxy)ethyl-rapamycin 40-O-(2-Nicotinoyloxy)ethyl-rapamycin, 40-O-[2-(N-Morpholino)acetoxy]ethyl-rapamycin 40-O-(2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-O-[2-(N-Methyl-N'-piperazinyl)acetoxy]ethyl-rapamycin, 39-O-Desmethyl-39,40-O,O-ethylene-rapamycin, (26R)-26-Dihydro-40-O-(2-hydroxy)ethyl-rapamycin, 28-O-Methyl-rapamycin, 40-O-(2-Aminoethyl)-rapamycin, 40-O-(2-Acetaminoethyl)-rapamycin 40-O-(2-Nicotinamidoethyl)-rapamycin, 40-O-(2-(N-Methyl-imidazo-2'-ylcarbethoxamido)ethyl)-rapamycin, 40-O-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-O-(2-Tolylsulfonamidoethyl)-rapamycin, 40-O-[2-(4',5'-Dicarboethoxy-1',2',3'-triazol-1'-yl)-ethyl]-rapamycin, 42-deoxy-42-(1H-tetrazol-1-yl)-, (42S)-rapamycin (Zotarolimus) 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin (temsirolimus), and tacrolimus.

Amorphous rapamycin like compounds, for example, sirolimus, may be prepared or processed in a manner such that it is in a stable form that may be administered in any number of ways. For example, the sirolimus may be administered orally, parenterally, intravascularly, intranasally,

- 4 -

intrabronchially, transdermally, rectally or via a coated medical device such as a stent coated with sirolimus.

In the exemplary embodiment described herein, a crystalline rapamycin like compounds such as sirolimus may be processed into a substantially solvent free amorphous solid form. For example sirolimus may be processed into an amorphous form with a glass transition temperature of from about 91 to about 95 °C and preferably about 93 °C. The glass transition is a property of amorphous materials. When an amorphous material is heated to a temperature above its glass transition temperature, the molecules comprising the material are more mobile, which in turn means that they are more active and thus more prone to reactions such as oxidation. However, when an amorphous material is maintained at a temperature below its glass transition temperature, its molecules are substantially immobilized and thus less prone to reactions such as oxidation. Accordingly, the higher the glass transition temperature for a given amorphous material, the more stable or less reactive the material is under room temperature and pressure (RTP) conditions.

Amorphous rapamycin like compounds may be prepared by mixing crystalline rapamycin like compounds with an appropriate solvent such as 2-propanol. The amount of solvent that may be used will depend on the solubility of the particular rapamycin like compounds in the specific solvent and the mixing conditions (e.g. temperature, mixing device used and the like). Preferably the amount of solvent used will be in the range of from about 2 ml to about 10 ml per gram of rapamycin like compound more preferably about 3 ml to about 5 ml per gram of rapamycin. The mixture may be heated and/or stirred to facilitate dissolution of the rapamycin like compounds (provided the heating is below the degradation temperature of the rapamycin like compound). The rapamycin like compound in solution

- 5 -

may then be precipitated from the solution by adding an agent, which causes the rapamycin like compound to be precipitated from the solution. The preferred agent is water. The precipitate formed by this process is amorphous rapamycin like compound. The mixture of the precipitate, solvent and agent may then be used in the preparation of products and dosage forms or the precipitate may be separated from the solvent and/or agent. Suitable methods of separating the precipitate from the mixture are well known to those of ordinary skill in the arts and include but not limited to drying, filtration, centrifugation and the like. It is currently preferred that the precipitate be separated from the mixture by filtration and the precipitate be washed with a suitable liquid in which the rapamycin like compound is not soluble in or has a very low solubility in under the wash conditions. The amorphous rapamycin like compound produced by this process may then be dried in a manner suitable to retain its substantially amorphous form. Preferably the amorphous rapamycin like compound will be substantially amorphous and have less than about 30 weight percent crystalline rapamycin like compound (e.g. crystalline sirolimus), more preferably less than about 10 weight percent crystalline rapamycin like compound (e.g. crystalline sirolimus), most preferably less than about 5 weight percent crystalline rapamycin like compound (e.g. crystalline sirolimus) and even more preferably less than about 1 weight percent crystalline rapamycin like compound (e.g. crystalline sirolimus). In one embodiment of the present invention the amorphous rapamycin like compound is preferably 100 weight percent amorphous rapamycin. In another embodiment of the present invention crystalline rapamycin like compounds can be added to the amorphous rapamycin like compound to vary the percentage of crystalline to amorphous rapamycin like compound.

In one exemplary embodiment of the present invention there is provided a method of preparing a substantially solvent free amorphous

- 6 -

sirolimus with a glass transition temperature, T_g , of from about 91 to about 95 °C and preferably about 93 °C comprising the following steps. First, a given amount of crystalline sirolimus is dissolved in an appropriate solvent. In the exemplary embodiment, 250 mg of crystalline sirolimus is placed in a 100 ml beaker to which 4 ml of 2-propanol is added. The mixture may be slightly heated and mixed to facilitate the dissolution of the sirolimus. Next, the solution is stirred while an agent is added to the solution to precipitate the sirolimus from solution. In the exemplary embodiment, the solution is continuously stirred with a magnetic stirrer while 50 ml of water is added in order to precipitate the amorphous sirolimus. The product of this step is an amorphous precipitate. The concentration of sirolimus in solution determines the length of time required to precipitate the sirolimus from solution. Next, the amorphous precipitate is filtered and washed. In the exemplary embodiment, the amorphous precipitate is passed through a 0.45 μm pore filter under vacuum to remove the supernatant. The filtered amorphous precipitate is then washed with 100 ml of water to remove impurities. In the next and final step, the precipitate is dried. In the exemplary embodiment, the precipitate is dried for a period ranging from 18 hours to about 36 hours at a temperature of about 30 °C and under a vacuum of about 150 mBar. The result is a substantially solvent free amorphous solid form of sirolimus with a glass transition temperature of about 93 °C that may be utilized in a polymer as described herein or in any other suitable dosage form as described herein.

A number of tests or evaluations may be performed in order that the substantially solvent free amorphous sirolimus may be characterized. In one test, the amorphous sirolimus is analyzed utilizing a micro attenuated total reflectance (ATR) infrared spectrometer. Essentially, the purpose of this test is to determine if the amorphous sirolimus prepared by the above-described process is degraded in any significant way. Table 1, given below, contains a

- 7 -

summary of the test parameters. Figure 1 is the ATR-infrared spectrum of amorphous sirolimus prepared utilizing the above-described process. As illustrated in Figure 1, the infrared spectrum of the prepared sirolimus reflects the vibrational modes of the molecular structure of sirolimus. In other words, the sirolimus was not degraded during the process.

TABLE 1 Micro Attenuated Total Reflectance Infrared Spectroscopy

Number of scans:	32
Resolution:	1 cm ⁻¹
Wavelength range:	4000 to 400 cm ⁻¹
Apparatus:	NICOLET MAGNA 560 FTIR SPECTROPHOTOMETER ¹
Baseline correction:	yes
Detector:	DTGS ² with KBr windows
Beam splitter:	Ge on KBr
Micro ATR accessory:	HARRICK SPLIT PEA with Si crystal

In another test, the amorphous sirolimus is analyzed utilizing differential scanning calorimetry. Essentially, the purpose of this test is to determine the glass transition temperature of the amorphous sirolimus. In this test, approximately 3 mg of amorphous sirolimus is transferred into a standard aluminum TA-Instrument sample pan and covered. The DSC curve is recorded on a TA-Instruments Q1000 MTDSC equipped with a RCS cooling unit. Table 2, given below, contains a summary of the test parameters. Figure 2 illustrates a differential scanning calorimetry curve of amorphous sirolimus. The differential scanning calorimetry curve shows the glass transition temperature of the amorphous sirolimus to be about 93 °C.

Table 2 Differential Scanning Calorimetry Settings

First Heating	
Initial temperature	40°C
Heating rate	2°C/min
Final temperature	30 ml/min
Nitrogen flow	30 ml/min
Amplitude	0.318°C
Period	60 s

In another test, the amorphous sirolimus is analyzed utilizing a thermogravimeter. Essentially, the purpose of this test is to determine weight loss in the amorphous sirolimus. In this test, the amorphous sirolimus is transferred into an aluminum sample pan and placed in a thermogravimeter. The TG curve is recorded utilizing a TA Instruments HI-RES TGA 2950 thermogravimeter. Table 3, given below, contains a summary of the test parameters. Figure 3 illustrates a thermogravity curve of amorphous sirolimus. As is illustrated, a loss of sample weight occurs from about 25 °C to about 160 °C. This small weight loss may be due to the evaporation of absorbed water and 2-propanol. A second weight loss is observed when the compound decomposes.

Table 3 Thermogravimetry Parameters

Initial temperature:	Room Temperature
----------------------	------------------

- 9 -

Heating rate:	20°C/min
Resolution factor:	4
Final condition:	300°C or <80[(w/w)%]

In yet another test, the amorphous sirolimus is analyzed utilizing a gas chromatograph. Essentially, the purpose of this test is to determine the chemical composition of the sample, in particular, the residual solvent content. In this test, 15 mg of amorphous sirolimus is placed in a vial and dissolved in 2 ml of DMSO. The vial is closed and analyzed utilizing the parameters listed in Table 4, given below. The results of the test indicate that the amorphous sirolimus contains 77 ppm of 2-propanol.

Table 4 Gas Chromatography

GC system	Parameters
Column	50 m fused silica column with an ID of 0.32 mm, coated with a chemically bonded polydimethylsiloxane (CP-SIL 5 CB) of 5 µm film thickness. comment:
Carrier gas	Gas: nitrogen 5.5 Gas: Hydrogen Pi: 100 kPa Mode: constant pressure comment:
Injector	Type: Splitter dynamic splitting: 0 – 30 ml/min split insert: fritted temperature: 230 °C comment:
Detector	Type: FID Temperature: 270 °C gases: hydrogen: 23 – 31 ml/min air: 285 – 315 ml/min make up: 20 – 25 ml/min sensitivity: range 12 (1 x 10 ³ pA/V) comment:

- 10 -

Headspace autosampler	Bath temperature:		80 °C			
	Loop temperature:		230 °C			
Temperature program	Loop volume:		5 ml			
	Equilibration time:		55 min			
	Pressure time on vial:		2 min			
	Pressure hold time:		0.2 min			
	Loop fill time:		1 min			
	Loop equilibration time:		0.2 min			
	Injection time:		0.5 min			
	Transfer line temperature:		230 °C			
	Vial pressure:		~50 kPa			
	Transfer line pressure:		~120 kPa			
Temperature program	Step	start temp. in °C	rate in °C/min.	end temp. in °C	hold time in min.	run time in min.
	1	40	0	40	0.5	0-0.5
	2	40	5	165	0	0.5-25.5
	3	165	30	220	8	25.5-35.3
	comment: step 3 is started approximately 2 minutes after elution of chlorobenzene					

In another test the amorphous sirolimus is analyzed using High Pressure Liquid Chromatography-Mass Spectrometry (LC-MS). Table 5, given below, contains a summary of the test parameters. Essentially, the purpose of this test is to determine if the amorphous sirolimus prepared by the above-described process is degraded in any significant way. Figure 4 is the LC-MS trace of amorphous sirolimus prepared utilizing the above-described process. LC-MS analysis on solvent free amorphous rapamycin prepared by the above-described process confirmed the formula by accurate mass. In other words, the sirolimus was not degraded during the process.

Table 5 High Pressure Liquid Chromatography-Mass Spectrometry (LC-MS)

HPLC System	Parameters
Column	Hypersil BDS – 10 cm x 4 mm I.D. and 3 µm particle size
	comment:
Column temperature	30 °C
	comment:
Flow rate	1.2 ml/min

- 11 -

HPLC System	Parameters								
	comment:								
Injection volume	5 µl								
	comment:								
Mobile phase	preparation and composition								
	A	0.5% ammonium acetate in water							
	B	acetonitrile							
	comment:								
Gradient	solvent	time in min.							
		0	15	17					
	%A	90	0	0					
	%B	10	100	100					
	comment: analytical run time is 15 minutes								

The term “**subject**” as used herein, refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or experiment.

The term “**therapeutically effective amount**” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.

As used herein, the term “**composition**” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.

- 12 -

The present invention further comprises pharmaceutical compositions containing one or more amorphous rapamycin like compounds with a pharmaceutically acceptable carrier. Currently the preferred amorphous rapamycin like compounds is amorphous srolimus. Pharmaceutical compositions containing one or more amorphous rapamycin like compounds described herein as the active ingredient can be prepared by intimately mixing the compound or compounds with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). Thus for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations, such as powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations may also be coated with substances such as sugars or be enteric-coated so as to modulate major site of absorption. For parenteral administration, the carrier will usually consist of sterile water and other ingredients may be added to increase solubility or preservation. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives.

To prepare the pharmaceutical compositions of this invention, one or more compounds of the present invention as the active ingredient is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for

- 13 -

example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, caplets, gelcaps, geltabs and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per unit dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.01 mg to about 6 mg and may be given at a dosage of from about 0.1 mg to about 2 mg and preferably from about 0.5 mg to about 1 mg. The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.

Preferably these pharmaceutical compositions are in unit dosage forms from such as tablets, capsules, caplets, gelcaps, geltabs, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral

- 14 -

parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the pharmaceutical composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, capsules, caplets and the like. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.01 mg to about 6 mg, preferably, from about 0.1 mg to about 2 mg, and more preferably from about 0.5 mg to about 1 mg of the active ingredient of the present invention. The tablets, capsules and caplets of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet, capsules, or caplets can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer, which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of material can be used for such enteric layers or coatings, such

- 15 -

materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the amorphous rapamycin like compounds of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions, include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

The method described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.01 mg to about 6 mg, preferably about 0.1 mg to about 2 mg and more preferably from about 0.5 mg to about 1 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as tablets, caplets, capsules and the like (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.

- 16 -

Advantageously, one or more of the compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, the amorphous rapamycin like compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.

For instance, for oral administration in the form of a tablet or capsule, the amorphous rapamycin like compound can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The liquid forms in suitably flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.

- 17 -

The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The amorphous rapamycin like compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art.

The daily dosage of the products may be varied over a wide range from 0.01 to 6 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4, 6 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.01 mg/kg to about 1 mg/kg of body weight per day. Preferably, the range is from about 0.03 to about 0.2 mg/kg of body weight per day, most preferably, from about 0.03 to about 0.1 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.

Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.

- 18 -

SOLID DOSAGE FORM EXAMPLES

The following provide the preparation and evaluation of representative examples of rapamycin like compounds in solid dosage tablets.

PROSPECTIVE EXAMPLE 1

The following shows the preparation and potential evaluation of a 1 mg amorphous rapamycin like compounds in oral dosage tablet containing a 100 mg sugar overcoat.

Formula

Ingredients*	Amount
Amorphous Sirolimus	1 mg
PLURONIC F68 (poloxamer 188)	0.5 mg
Sucrose	98.940 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg
Water	49.653 mg

*A 2% overage is included in these quantities to account for manufacturing losses.

Manufacturing Directions

1. A dispersion of less than about 400 nm particle size of amorphous sirolimus and PLURONIC F68 (poloxamer 188) is prepared according to U.S. Pat. No. 5,145,684

- 19 -

using a 2:1 ratio of amorphous sirolimus:PLURONIC F68. A dispersion concentration of 150 mg amorphous sirolimus/ml is used.

2. Sucrose is added and mixed until the sucrose dissolved.
3. Povidone is added and mixed until well wetted. Mixing was continued vigorously until the povidone dissolved.
4. Microcrystalline cellulose is added, and is mixed well until wetted.
5. Water is added and is mixed well.
6. The resulting solution is spray coated onto a pharmaceutically inert core portionwise and is air dried in between portions.

PROSPECTIVE EXAMPLE 2

A 0.5 mg amorphous sirolimus oral dosage tablet containing a 100 mg sugar overcoat is prepared according the procedure described in Example 1. The dispersion contained a 2:1 ratio of amorphous sirolimus:PLURONIC F68 (poloxamer 188), and is used at a concentration of 150 mg amorphous sirolimus/ml. The following lists the quantities of ingredients will be used.

Formula

Ingredients*	Amount
Amorphous Sirolimus	0.5 mg
PLURONIC F68 (poloxamer 188)	0.25 mg
Sucrose	99.705 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg

- 20 -

Water	52.288 mg
-------	-----------

*A 2% overage is included in these quantities to account for manufacturing losses.

PROSPECTIVE EXAMPLE 3

A 3.0 mg amorphous sirolimus oral dosage tablet containing a 100 mg sugar overcoat is prepared according the procedure described in Example 1. The dispersion contained a 2:1 ratio of amorphous sirolimus:PLURONIC F68 (poloxamer 188), and is used at a concentration of 150 mg amorphous sirolimus/ml. The following lists the quantities of ingredients will be used.

Formula

Ingredients*	Amount
Amorphous Sirolimus	3.0 mg
PLURONIC F68 (poloxamer 188)	1.5 mg
Sucrose	95.880 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg
Water	39.113 mg

*A 2% overage is included in these quantities to account for manufacturing

- 21 -

losses.

PROSPECTIVE EXAMPLE 4

A 5.0 mg amorphous sirolimus oral dosage table containing a 100 mg sugar overcoat is prepared according the procedure described in Example 1. The dispersion contained a 2:1 ratio of amorphous sirolimus:PLURONIC F68 (poloxamer 188), and is used at a concentration of 150 mg amorphous sirolimus/ml. The following lists the quantities of ingredients will be used.

Formula

Ingredients*	Amount
Amorphous Sirolimus	5.0 mg
PLURONIC F68 (poloxamer 188)	2.5 mg
Sucrose	92.820 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg
Water	28.573 mg

*A 2% overage is included in these quantities to account for manufacturing losses.

PROSPECTIVE EXAMPLE 5

A 7.5 mg amorphous sirolimus oral dosage tablet containing a 100 mg sugar overcoat is prepared according the procedure described in Example 1. The

- 22 -

dispersion contained a 2:1 ratio of amorphous sirolimus:PLURONIC F68 (poloxamer 188), and is used at a concentration of 150 mg amorphous sirolimus/ml. The following lists the quantities of ingredients will be used.

Formula

Ingredients*	Amount
Amorphous Sirolimus	7.5 mg
PLURONIC F68 (poloxamer 188)	3.75 mg
Sucrose	88.995 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg
Water	15.398 mg

*A 2% overage is added to these quantities to account for manufacturing losses.

PROSPECTIVE EXAMPLE 6

A 10 mg amorphous sirolimus oral dosage tablet containing a 100 mg sugar overcoat is prepared according the procedure described in Example 1. The dispersion contained a 2:1 ratio of amorphous sirolimus:PLURONIC F68 (poloxamer 188), and is used at a concentration of 150 mg amorphous sirolimus/ml. The following lists the quantities of ingredients will be used.

- 23 -

Formula

Ingredients*	Amount
Amorphous Sirolimus	10 mg
PLURONIC F68 (poloxamer 188)	5 mg
Sucrose	5.170 mg
Povidone	0.510 mg
Microcrystalline cellulose	1.020 mg
Water	2.223 mg

*A 2% overage is included in these quantities to account for manufacturing losses.

IV DOSAGE FORM EXAMPLES

PROSPECTIVE EXAMPLE 7

Preparation of Sirolimus IV Concentrate in Dimethylacetamide (50 mg/ml)

Rapamycin like compound IV Concentrate in Dimethylacetamide (50 mg/ml)
Formula (Density - 0.944 g/ml):

Ingredients	Amount
Amorphous Sirolimus @ 100%	5.0 gm
Dimethylacetamide (DMA) qs	100 ml or 94.4 gm

- 24 -

Procedure:

1. Weigh the amorphous sirolimus into a suitable calibrated container.
2. Adjust volume to 100 ml with DMA.
3. Mix until a uniform solution results.
4. Sterile filter the solution.
5. Package into ampules and seal.

PROSPECTIVE EXAMPLE 8

Preparation of Amorphous Sirolimus IV Solution at 2.0 mg/ml

A. Diluent for amorphous Sirolimus IV at 2.0 mg/ml

Formula (Density - 1.081 gm/ml):

Ingredients	Amount
Polysorbate 80, NF	4.0 gm
Polyethylene Glycol 300, NF	50.0 gm
Water for Injection, USP qs	100 ml or 108.1 gm

Procedure:

1. Weigh the Polysorbate 80 into a suitable calibrated container.
2. Add the Polyethylene Glycol 300 to the container in Step #1.
3. Adjust to final volume with Water for Injection, USP.
4. Mix until uniform.
5. Filter the resulting solution.
6. Fill 12.0 ml.±.0.1 ml into each 20 ml flint vial, seal and crimp.

- 25 -

7. Autoclave to achieve sterility.

B. Amorphous Sirolimus IV solution at 2.0 mg/ml (constituted)

Formula (Density - 1.077 gm/ml):

Ingredients	Amount
Amorphous Sirolimus IV Concentrate @ 50 mg/ml	0.5 ml
Diluent for IV-Sirolimus	12.0 ml

Procedure:

1. Inject 0.5 ml of Amorphous Sirolimus IV Concentrate at 50 mg/ml into a vial containing 12.0 ml of diluents for IV-Sirolimus using good sterile technique.
2. Shake until a clear solution results.

PROSPECTIVE EXAMPLE 9

Preparation of Amorphous Sirolimus IV Solution at 4.0 mg/ml

A. Diluent for amorphous Sirolimus IV at 4.0 mg/ml

Formula (Density - 1.077 gm/ml):

Ingredients	Amount
Polysorbate 80, NF	8.0 gm
Polyethylene Glycol 300, NF	50.0 gm
Water for Injection, USP	qs 100 ml or 107.7 gm

- 26 -

Procedure:

1. Weigh the Polysorbate 80 into a suitably calibrated container.
2. Add the Polyethylene Glycol 300 to the container in Step #1.
3. Adjust to final volume with Water for Injection, USP.
4. Mix until uniform.
5. Filter the resulting solution.
6. Fill 5.75 ml.±.0.1 ml into each 10 ml flint vial, seal and crimp.
7. Autoclave to achieve sterility.

B. Amorphous Sirolimus IV solution at 4.0 mg/ml (constituted)

Formula (Density - 1.072 gm/ml):

Ingredients	Amount
Amorphous Sirolimus IV Concentrate @ 50 mg/ml	0.5 ml
Diluent for IV-Amorphous Sirolimus	5.75 ml

Procedure:

1. Inject 0.5 ml of Amorphous Sirolimus IV Concentrate at 50 mg/ml into a vial containing 5.75 ml of diluent for IV-Sirolimus using good sterile technique.
2. Shake until a clear solution results.

PROSPECTIVE EXAMPLE 10

- 27 -

The examples herein represent the batch production of ampules of sirolimus concentrate and vials of diluent for use in obtaining 0.1, 0.5, 2.0 and 4.0 mg/mL. The sirolimus IV solutions may be constituted for injection in the same manner as in Examples 2B and 3B.

A. Sirolimus IV Concentrate 50 mg/ml

	Claim/mL	Input/ Ampule	Representative Batch Formula 10,000 Ampules
Active Ingredient	0.050 g	0.0325 g	0.325 kg
Amorphous Rapamycin @ 100%			
Inactive Ingred-		0.65 mL or	6.50 L or
ients:		0.61 g	6.14 kg
Dimethyl acetamide qs ad			
Density = 0.944 g/mL			

B. Diluent for Sirolimus IV at 0.1 mg/mL

Active Ingredient	Input/Vial	Representative Batch Formula 10,000 Vials
Polysorbate 80, NF	4.00 g	40.0 kg
Polyethylene Glycol 300, NF	50.0 g	500 kg
Water for Injection, USP qs ad	100 mL or	1000 L or
	108 g	1081 kg
Density - 1.081 g/mL		

- 28 -

C. Diluent for Rapamycin IV at 0.5 mg/mL

Active Ingredient	Input/Vial	Representative Batch Formula 10.000 Vials
Polysorbate 80, NF	2.00 g	20.0 kg
Polyethylene Glycol 300, NF	25.0 g	250 kg
Water for Injection, USP qs ad	50.0 mL or	500 L or
	54.1 g	541 kg
Density - 1.081 g/mL		

D. Diluent for Rapamycin IV at 2 mg/mL

Active Ingredient	Input/Vial	Representative Batch Formula 10,000 Vials
Polysorbate 80, NF	0.480 g	4.80 kg
Polyethylene Glycol 300, NF	6.00 g	60.0 kg
Water for Injection, USP qs ad	12.0 mL or	120 L or
	13.0 g	130 kg
Density - 1.081 g/mL		

E. Diluent Rapamycin IV at 4 mg/mL

Active Ingredient	Input/Vial	Representative Batch Formula 10,000 Vials
-------------------	------------	---

- 29 -

Polysorbate 80, NF	0.460 g	4.60 kg
Polyethylene Glycol 300, NF	2.88 g	28.8 kg
Water for Injection, USP qs ad	5.75 mL or	57.5 L or
	6.19 g	61.9 kg
Density - 1.077 g/mL		

Note: A-E If the potency of sirolimus is less than 100%, the input must be adjusted to give claim potency.

Procedures for preparations A-E.

A. Sirolimus IV Concentrate at 50 mg/ml Procedure:

1. Weigh the amorphous sirolimus into a suitable calibrated container.
2. Add dimethylacetamide to achieve the appropriate volume or weight
3. Mix until a solution results.
4. Maintain sterile conditions throughout filtering, filling and sealing.
5. Filter the solution from Step #3 through a 0.2 micron filter.
6. Fill 0.65 mL $\pm$ 0.05 mL (0.61 g $\pm$ 0.05 g) of the solution from Step #5 into each 1 mL amber ampule and seal.
7. Store under refrigeration.

B. Sirolimus IV Diluent at 0.1 mg/ml Procedure:

1. Weigh the Polysorbate 80 into a suitable container.
2. Add the appropriate weight of the Polyethylene Glycol 300 to the container in Step #1.
3. Add Water for Injection to achieve the appropriate volume or weight.
4. Mix until a solution results.
5. Filter the solution from Step #4 through a 0.2 micron filter.
6. Fill 100 mL $\pm$ 0.2 mL (108 g $\pm$ 0.2 g) of the solution from Step #5 into each 100 mL flint vial, seal with a barrier faced stopper and crimp with an aluminum seal.

- 30 -

7. Sterilize by steam autoclave.
8. Store at room temperature or under refrigeration.

C. Sirolimus IV Diluent at 0.5 mg/ml Procedure:

1. Weigh the Polysorbate 80 into a suitable container.
2. Add the appropriate weight of the Polyethylene Glycol 300 to the container in Step #1.
3. Add Water for Injection to achieve the appropriate volume or weight.
4. Mix until a solution results.
5. Filter the solution from Step #4 through a 0.2 micron filter.
6. Fill 50 mL $\pm$.1 mL (54 g $\pm$.1.1 g) of the solution from Step #5 into each 100 mL flint vial, seal with a barrier faced stopper and crimp with an aluminum seal.
7. Sterilize by steam autoclave.
8. Store at room temperature or under refrigeration.

D. Sirolimus IV Diluent at 2 mg/ml Procedure:

1. Weigh the Polysorbate 80 into a suitable container.
2. Add the appropriate weight of the Polyethylene Glycol 300 to the container in Step #1.
3. Add Water for Injection to achieve the appropriate volume or weight.
4. Mix until a solution results.
5. Filter the solution from Step #4 through a 0.2 micron filter.
6. Fill 12.0 mL $\pm$.0.1 mL (13.0 g $\pm$.0.1 g) of the solution from Step #5 into each 20 mL flint vial, seal with a barrier faced stopper and crimp with an aluminum seal.
7. Sterilize by steam autoclave.
8. Store at room temperature or under refrigeration.

E. Sirolimus IV Diluent at 4 mg/ml Procedure:

1. Weigh the Polysorbate 80 into a suitable container.

- 31 -

2. Add the appropriate weight of the Polyethylene Glycol 300 to the container in Step #1.
3. Add Water for Injection to achieve the appropriate volume or weight.
4. Mix until a solution results.
5. Filter the solution from Step #4 through a 0.2 micron filter.
6. Fill 5.75 mL $\pm$ 0.1 mL (6.2 g $\pm$ 0.1 g) of the solution from Step #5 into each 10 mL flint vial, seal with a barrier faced stopper and crimp with an aluminum seal.
7. Sterilize by steam autoclave.
8. Store at room temperature or under refrigeration.

ORAL LIQUID DOSAGE FORM

PROSPECTIVE EXAMPLE 11

Sirolimus Oral at 1 mg/ml

A sirolimus oral formulation at a concentration of 1 mg/ml can be formulated from the following active and inactive ingredients by the procedural steps which follow:

	Conc.	Input	Batch Formula 10,000 bottles
Active Ingredient:	1.00 mg/ml	0.025 g	0.250 kg
Amorphous sirolimus @ 100%			
<u>Inactive Ingredients:</u>			
Polysorbate 80, NF	10.8 mg/ml	0.270 g	2.700 kg
Phosal 50 PG .RTM	1.00 ml	25.0 ml	250.0 L
propylene glycol			
and lecithin q.s. ad			

- 32 -

or	1.005 gm	25.125 g	251.25 kg
----	----------	----------	-----------

Density of the Final Formulation 1.005 g/ml

If the potency of the amorphous sirolimus is less than 100%, the input must be adjusted to achieve the claimed potency.

Method of Manufacture

Procedure:

1. Weigh the amorphous sirolimus into a suitable container.
2. Add the Polysorbate 80 to the container in step #1
3. Adjust to the final volume with Phosal 50 PG.
4. Mix until the amorphous sirolimus is dissolved.
5. Fill 25 ml, $\pm$ 1.25 ml (25.125 g, $\pm$ 1.256 g) into each one ounce amber glass bottle. It is preferable to seal with a child resistant cap.

For improved wettability and ease of solution, an alternative order of addition of the ingredients and amounts presented above is as follows:

1. Polysorbate 80.
2. A portion of the Phosal 50 PG propylene glycol and lecithin.
3. Amorphous Sirolimus.
4. The remaining Phosal 50 PG propylene glycol and lecithin. The amorphous sirolimus in these formulations may also be comminuted by use of a mill or mortar

- 33 -

and pestle and passed through an 80 mesh screen.

PROSPECTIVE EXAMPLE 12

Sirolimus Oral at 5 mg/ml

A sirolimus oral formulation at a concentration of 5 mg/ml can be formulated from the following active and inactive ingredients by the procedural steps which follow:

	Conc.	Input	Batch Formula 10,000 bottles
Active Ingredient:	5.00 mg	0.125 g	1.250 kg
Amorphous Sirolimus @ 100%			
Inactive Ingredients:			
Polysorbate 80, NF	10.8 mg	0.270 g	2.70 kg
Phosal 50 PG	1.00 ml	25.0 ml	250.0 L
propylene glycol and lecithin q.s. ad			
or	1.005 gm or	25.125 g or	251.25 kg
Density of the Final Formulation 1.005 g/ml.			

If the potency of the amorphous sirolimus is less than 100%, the input must be adjusted to give the claimed potency.

- 34 -

The procedural steps for formulation and storage of the 5 mg/ml oral sirolimus formulation are the same as those listed in Example 1, as are the alternative order of addition of ingredients and the methods of comminution.

PROSPECT EXAMPLE 13

The formulation of this Example 13 can be produced using the ingredients which follow and the methods indicated below:

Ingredients	Amount
Amorphous Sirolimus @ 100% up to	1.0 gm
Polysorbate 80, NF	1.0 ml or 1.08 gm
Phosal 50 PG lecithin and propylene glycol	100 ml or 100.5 gm
q.s.	

Method of Formulation

1. Weigh the amorphous rapamycin into a suitable container.
2. Add the Polysorbate 80 into the container of Step #1.
3. Adjust to the final volume with Phosal 50 PG.RTM. propylene glycol and lecithin.
4. Mix until a solution results.

Alternatively, this formula can be packaged in a suitable container or encapsulated into a capsule.

- 35 -

PROSPECTIVE EXAMPLE 14

Formula	Ingredients
Amorphous Rapamycin @ 100% up to	2.5 grams
Polysorbate 80, NF	5.0 ml or 5.4 gm
Absolute Ethanol	12.67 ml or 10.0 gm
Phosal 50 PG lecithin and propylene glycol	100 ml
q.s.	

This formulation can be produced by the following steps:

1. Weigh the amorphous rapamycin into a suitable container
2. Add the absolute ethanol to the container in Step #1. Mix until dissolved.
3. Add the polysorbate 80 to the container in Step #2. Mix until uniform.
4. Add Phosal 50 PG lecithin and propylene glycol to adjust to the final volume.
5. Mix until uniform.

Alternatively, this formula can be packaged in a suitable container or encapsulated into a capsule.

PROSPECTIVE EXAMPLE 15

The oral formulations of this invention, such as those disclosed above, may also be prepared in encapsulated forms, such as formulations within starch or SEG capsules.

- 36 -

The following procedure describes a method which may be utilized to prepare such encapsulated formulations.

Procedure:

- 1) Add to a container, NF, the Polysorbate 80.
- 2) Add to the Polysorbate 80 of Step #1 80% of the the required Phosal 50 PG.
- 3) Weigh the amorphous sirolimus component of the formulation into the container of Step #2.
- 4) Adjust to the final formulation weight with Phosal 50 PG.
- 5) Establish a nitrogen atmosphere over the formulation and maintain until the capsules are filled.
- 6) Mix the formulation until the amorphous sirolimus is dissolved.
- 7) Pass the formulation solution through a particulate (such as a 100 mesh screen) or scintered glass filter.
- 8) Fill 0.50 ml of the Step #7 material into capsule shells using an automatic syringe dispensing unit and seal the capsule.
- 9) Package the filled capsules upon completion of encapsulation. An example of a preferred package is a conventional blister package with a perforable metal foil backing.
- 10) Optionally store the finished encapsulated product at refrigerated conditions (2°.- 8° C.) protected from light.

- 37 -

The primary capsule sealant for the starch capsule may be a 5% Dextrin, NF, aqueous solution. It is preferable to heat purified water to 50°-60°C. prior to compounding to facilitate dissolution of the Dextrin. Prior to use it is also preferable to filter the Dextrin solution through a suitable particulate filter.

PROSPECTIVE EXAMPLE 16

Bioavailability

The bioavailability of any of the formulation provided above or in the specification may be determined by methods known in the art. Suitable methods for testing such bioavailability include but are not limited to:

- a) Testing the formulation in cynomolgus monkeys. Cynomolgus monkeys may be administered the formulations provided above, at appropriate doses and the serum concentrations may be determined over time after dosing to determine the optimum dosage profile:
- b) Formulations containing an amorphous rapamycin like compound at appropriate concentrations, prepared as described above, may be administered to healthy male human volunteers between the ages of 18 and 45, from whom blood samples were drawn at the time intervals table below. The sirolimus blood samples may be assayed for whole blood sirolimus concentration using a validated (ESP)-HPLC-MS method.

- 38 -

One appropriate example of time intervals to test blood concentrations would be as follows:

Time Interval Following Administration (Hours)	Blood Concentration (conc. = ng/ml)
0.33	
0.67	
1	
2	
3	
4	
5	
8	
12	
18	
24	
48	

- 39 -

We Claim:

1. A pharmaceutical dosage form comprising substantially amorphous rapamycin like compounds and a pharmaceutically acceptable excipient.
2. The pharmaceutical dosage form of claim 1 wherein the substantially amorphous rapamycin like compound is sirolimus.
3. The pharmaceutical dosage form of claim 2 wherein the substantially amorphous sirolimus contains less than 30 weight percent crystalline sirolimus.
4. The pharmaceutical dosage form of claim 2 wherein the substantially amorphous sirolimus contains less than 10 weight percent crystalline sirolimus.
5. The pharmaceutical dosage form of claim 2 wherein the substantially amorphous sirolimus contains less than 5 weight percent crystalline sirolimus.
6. The pharmaceutical dosage form of claim 2 wherein the substantially amorphous sirolimus contains less than 1 weight percent crystalline sirolimus.
7. The pharmaceutical dosage form of claim 2 wherein per unit dose the pharmaceutical dosage form contains from about 0.1 mg to about 2 mg of the sirolimus.
8. The pharmaceutical dosage form of claim 2 per unit dose the pharmaceutical dosage form contains from about 0.5 mg to about 1 mg of the sirolimus.
9. The pharmaceutical dosage form of claim 1 where the pharmaceutical dosage form is a solid dosage form.


- 40 -

10. The pharmaceutical dosage form of claim 7 wherein the solid dosage form is selected from the group consisting of tablets, capsules, caplets, gelcaps, geltabs, powders and granules.
11. The pharmaceutical dosage form of claim 8 wherein the solid dosage form is selected from the group consisting of tablets, capsules, gelcaps and geltabs.
12. The pharmaceutical dosage form of claim 11 wherein the rapamycin like compound is sirolimus.
13. The pharmaceutical dosage form of claim 1 wherein the dosage form is an oral dosage form.
14. The pharmaceutical dosage form of claim 13 wherein the rapamycin like compound is sirolimus.
15. The pharmaceutical dosage form of claim 1 wherein the dosage form is an injectable dosage form.
16. The pharmaceutical dosage form of claim 15 wherein the like compound is sirolimus.
17. The pharmaceutical dosage form of claim 1 wherein the pharmaceutical dosage form is a suspension containing amorphous rapamycin.
18. A process for making a pharmaceutical dosage form comprising admixing a substantially amorphous rapamycin like compound with at least one pharmaceutically acceptable excipient.


- 41 -

19. The pharmaceutical dosage form of claim 18 wherein the like compound is sirolimus.

1/4

FIG. 1

2/4

FIG. 2

3/4



FIG. 3

FIG. 4



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2005/034433

A. CLASSIFICATION OF SUBJECT MATTER

A61K9/14 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2005/023254 A (WYETH; BENJAMIN, ERIC, J; ASHRAF, MUHAMMAD; JAIN, ASHWINKUMAR) 17 March 2005 (2005-03-17) page 1, line 25 - page 24, line 18; claims 1-80; examples 1-7	1-11, 13, 15, 17, 18
X	US 6 004 973 A (GUITARD ET AL) 21 December 1999 (1999-12-21)	1-11, 13, 15, 17, 18
Y	column 2, lines 6-11, 16-20; claim 10 column 5, line 48 - column 6, line 5 column 6, lines 6-9 claims 1-15; examples 1-4	12, 14, 16, 19
	----- -/-- -----	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

23 December 2005

Date of mailing of the international search report

04/01/2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Toulacis, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/034433

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2002/032213 A1 (NAVARRO FRANCOIS ET AL) 14 March 2002 (2002-03-14) paragraphs '0010!, '0018!, '0019!, '0030!, '0032!, '0033!, '0041!, '0042!; claims 1-13; examples 1,2	1-11,13, 15,17,18
Y	-----	12,14, 16,19
Y	EP 1 281 400 A (NOVARTIS AG; NOVARTIS PHARMA GMBH) 5 February 2003 (2003-02-05) the whole document -----	12,14, 16,19

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US2005/034433

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2005023254	A	17-03-2005	NONE	
US 6004973	A	21-12-1999	AT 258429 T	15-02-2004
			AU 706174 B2	10-06-1999
			AU 6615296 A	18-02-1997
			BE 1009856 A5	07-10-1997
			BR 9609537 A	23-02-1999
			CA 2225960 A1	06-02-1997
			CA 2426956 A1	06-02-1997
			CN 1195289 A	07-10-1998
			CZ 9800091 A3	15-04-1998
			DE 69631422 D1	04-03-2004
			DE 69631422 T2	04-11-2004
			DK 839028 T3	01-06-2004
			WO 9703654 A2	06-02-1997
			EP 0839028 A2	06-05-1998
			ES 2215195 T3	01-10-2004
			FR 2736550 A1	17-01-1997
			HK 1016081 A1	16-08-2002
			HU 9900391 A2	28-06-1999
			IL 122905 A	06-07-2003
			IT RM960501 A1	12-01-1998
			JP 11509223 T	17-08-1999
			JP 2004002457 A	08-01-2004
			NO 980081 A	08-01-1998
			NO 20025089 A	18-01-1998
			NZ 313633 A	28-05-1999
			PL 324502 A1	25-05-1998
			PT 839028 T	31-05-2004
			RU 2159107 C2	20-11-2000
			SK 4498 A3	06-05-1998
			SK 283572 B6	11-09-2003
			TR 9800045 T1	21-05-1998
			US 6197781 B1	06-03-2001
US 2002032213	A1	14-03-2002	AU 759219 B2	10-04-2003
			AU 1657300 A	26-06-2000
			BE 1012869 A3	03-04-2001
			BR 9915986 A	04-09-2001
			CA 2351580 A1	15-06-2000
			CN 1374872 A	16-10-2002
			CZ 20012001 A3	12-09-2001
			WO 0033878 A2	15-06-2000
			EP 1137439 A2	04-10-2001
			FR 2786771 A1	09-06-2000
			HU 0104489 A2	28-03-2002
			ID 29250 A	16-08-2001
			IT MI992520 A1	04-06-2001
			JP 2002531527 T	24-09-2002
			JP 2005200429 A	28-07-2005
			NO 20012424 A	16-05-2001
			NZ 511936 A	31-10-2003
			NZ 527781 A	26-11-2004
			PL 348333 A1	20-05-2002
			SK 7662001 A3	03-12-2001
			TR 200101416 T2	21-01-2002
			TR 200201428 T2	23-12-2002

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/034433

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 1281400	A	05-02-2003	SI
		839028 T1	30-06-2004